Restasis purchasers win class cert
A federal judge has certified a class of indirect purchasers alleging that Allergan monopolised the market for dry-eye medication Restasis through sham petitioning to the Food and Drug Administration.
Subscribe to Global Competition Review
Subscribe and start reading now
Already have access? Login below
Copyright © Law Business ResearchCompany Number: 03281866 VAT: GB 160 7529 10